Centre of Excellence for Autoimmunity in Cancer
  • Print

University of Nottingham sells shares in spin-out company Oncimmune


The University of Nottingham has sold 4.3 million shares in one of its spin-out companies, Oncimmune, raising over £5 million to support the University’s research and teaching activities.

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary test for early cancer detection: EarlyCDT®. The company has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. 

The earlier identification of cancer leads to better outcomes, less aggressive treatments and increased survival rates. Oncimmune’s first product, EarlyCDT®-Lung, was launched in 2012 and since then over 150,000 commercial tests have been sold. 

The company was founded on the research work of Professor John Robertson, a research active clinical oncologist, based in the Faculty of Medicine and Health Sciences.

His research project led to the formation of the spin-out company in 2002, which was publicly listed on AIM in 2016. The University's shares in Oncimmune were acquired through an initial shareholding at formation of the spin-out, followed by further investment from the University over the intervening years.

The sale of Oncimmune shares is in line with University policy and has generated a substantial return. In addition, the University retains 2.2 million shares which will allow the University to benefit if the share price increases further as the company continues to develop.

Read more.

Posted on Thursday 8th February 2018

Centre for Excellence for Autoimmunity in Cancer (CEAC)
Graduate Entry Medicine & Health
Royal Derby Hospital
Uttoxeter Road
DE22 3DT

telephone: +44 (0)1332 724880
fax: +44 (0)1332 724880
email: CEAC@nottingham.ac.uk